Literature DB >> 24041886

Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners.

Sandirai Musuka1, Shashikant Srivastava, Chandima Wasana Siyambalapitiyage Dona, Claudia Meek, Richard Leff, Jotam Pasipanodya, Tawanda Gumbo.   

Abstract

Phenothiazines are being repurposed for treatment of tuberculosis. We examined time-kill curves of thioridazine and first-line drugs against log-growth-phase and semidormant bacilli under acidic conditions and nonreplicating persistent Mycobacterium tuberculosis. While both the potency and the efficacy of first-line drugs declined dramatically as M. tuberculosis replication rates decreased, those of thioridazine improved. The mutation prevalence to 3 times the thioridazine MIC was <1 × 10(-11), better than for ≥2 first-line drugs combined. Hollow fiber system studies revealed that the relationship between sterilizing effect and pharmacodynamic indices (PDI) was characterized by an r(2) of 0.88 for peak/MIC, an r(2) of 0.47 for the area under the concentration-time curve (AUC) to MIC, and an r(2) of 0.14 for the cumulative percentage of a 24-h period that the drug concentration exceeds the MIC under steady-state pharmacokinetic conditions (%TMIC) at the end of the first week. However, the PDI linked to effect "wobbled" as the duration of therapy increased, so that by the fourth week the r(2) was 0.88 for AUC/MIC, 0.78 for %TMIC, and 0.72 for peak/MIC. This "wobble" has implications on general pharmacokinetic/pharmacodynamic theory, whereby efficacy is linked to only one of the three PDIs in deterministic models. The potency changed 8.9-fold from the first to the fourth weeks. The non-protein-bound AUC/MIC associated with maximal kill at the end of therapy was 50.53 (protein binding = 99.5%). This thioridazine exposure was calculated to extinguish all three M. tuberculosis metabolic populations in human lungs in only 42.9 days of monotherapy. However, this concentration exceeds the 2- to 8-mg/liter thioridazine concentration in serum known to be lethal to humans. Therefore, the way forward for phenothiazine monotherapy that also reduces therapy duration is via synthesis of less toxic congeners.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24041886      PMCID: PMC3837896          DOI: 10.1128/AAC.00829-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  61 in total

1.  Photosensitization of DNA strand breaks by three phenothiazine derivatives.

Authors:  Giampietro Viola; Loredana Latterini; Daniela Vedaldi; Gian Gaetano Aloisi; Francesco Dall'Acqua; Nadia Gabellini; Fausto Elisei; Arianna Barbafina
Journal:  Chem Res Toxicol       Date:  2003-05       Impact factor: 3.739

2.  Clinical, biochemical and post mortem studies on a patient treated with chlorpromazine.

Authors:  F M FORREST; I S FORREST; L ROIZIN
Journal:  Agressologie       Date:  1963 May-Jun

3.  Totally drug-resistant tuberculosis in India.

Authors:  Zarir F Udwadia; Rohit A Amale; Kanchan K Ajbani; Camilla Rodrigues
Journal:  Clin Infect Dis       Date:  2011-12-21       Impact factor: 9.079

4.  STREPTOMYCIN treatment of pulmonary tuberculosis.

Authors: 
Journal:  Br Med J       Date:  1948-10-30

5.  Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB.

Authors:  Seok-Yong Eum; Ji-Hye Kong; Min-Sun Hong; Ye-Jin Lee; Jin-Hee Kim; Soo-Hee Hwang; Sang-Nae Cho; Laura E Via; Clifton E Barry
Journal:  Chest       Date:  2009-09-11       Impact factor: 9.410

6.  Excited-state properties and in vitro phototoxicity studies of three phenothiazine derivatives.

Authors:  Fausto Elisei; Loredana Latterini; Gian Gaetano Aloisi; Ugo Mazzucato; Giampietro Viola; Giorgia Miolo; Daniela Vedaldi; Francesco Dall'Acqua
Journal:  Photochem Photobiol       Date:  2002-01       Impact factor: 3.421

7.  Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis.

Authors:  Ramesh Jayaram; Radha K Shandil; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharath; E Kantharaj; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

8.  Chlorpromazine: a drug potentially useful for treating mycobacterial infections.

Authors:  A J Crowle; G S Douvas; M H May
Journal:  Chemotherapy       Date:  1992       Impact factor: 2.544

9.  Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.

Authors:  Ramesh Jayaram; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharat; R K Shandil; E Kantharaj; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

10.  A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients.

Authors:  Jotam G Pasipanodya; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

View more
  23 in total

1.  Susceptibility Testing of Antibiotics That Degrade Faster than the Doubling Time of Slow-Growing Mycobacteria: Ertapenem Sterilizing Effect versus Mycobacterium tuberculosis.

Authors:  Shashikant Srivastava; Sander P van Rijn; A Mireille A Wessels; Jan-Willem C Alffenaar; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

2.  Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary Disease.

Authors:  Beatriz E Ferro; Shashikant Srivastava; Devyani Deshpande; Jotam G Pasipanodya; Dick van Soolingen; Johan W Mouton; Jakko van Ingen; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 3.  Energy metabolism and drug efflux in Mycobacterium tuberculosis.

Authors:  Philippa A Black; Robin M Warren; Gail E Louw; Paul D van Helden; Thomas C Victor; Bavesh D Kana
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

4.  Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing.

Authors:  Sander P van Rijn; Shashikant Srivastava; Mireille A Wessels; Dick van Soolingen; Jan-Willem C Alffenaar; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

5.  d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.

Authors:  Devyani Deshpande; Jan-Willem C Alffenaar; Claudio U Köser; Keertan Dheda; Moti L Chapagain; Noviana Simbar; Thomas Schön; Marieke G G Sturkenboom; Helen McIlleron; Pooi S Lee; Thearith Koeuth; Stellah G Mpagama; Sayera Banu; Suporn Foongladda; Oleg Ogarkov; Suporn Pholwat; Eric R Houpt; Scott K Heysell; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

6.  Multiparameter Responses to Tedizolid Monotherapy and Moxifloxacin Combination Therapy Models of Children With Intracellular Tuberculosis.

Authors:  Devyani Deshpande; Shashikant Srivastava; Eric Nuermberger; Thearith Koeuth; Katherine R Martin; Kayle N Cirrincione; Pooi S Lee; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

7.  Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges.

Authors:  Gesham Magombedze; Jotam G Pasipanodya; Shashikant Srivastava; Devyani Deshpande; Marianne E Visser; Emmanuel Chigutsa; Helen McIlleron; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

8.  The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis.

Authors:  Shashikant Srivastava; Devyani Deshpande; Eric Nuermberger; Pooi S Lee; Kayle Cirrincione; Keertan Dheda; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

9.  Sterilizing activity of thioridazine in combination with the first-line regimen against acute murine tuberculosis.

Authors:  Noton K Dutta; Michael L Pinn; Petros C Karakousis
Journal:  Antimicrob Agents Chemother       Date:  2014-06-16       Impact factor: 5.191

10.  Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease.

Authors:  Beatriz E Ferro; Shashikant Srivastava; Devyani Deshpande; Jotam G Pasipanodya; Dick van Soolingen; Johan W Mouton; Jakko van Ingen; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.